Scarica l'app Stockscreener
15.04
6.64%
0.927
Dopo l'orario di chiusura:
15.05
0.013
+0.09%
Precedente Chiudi:
$14.11
Aprire:
$14.07
Volume 24 ore:
1.28M
Relative Volume:
0.91
Capitalizzazione di mercato:
$1.65B
Reddito:
$-665.00K
Utile/perdita netta:
$-149.28M
Rapporto P/E:
-8.3553
EPS:
-1.7997
Flusso di cassa netto:
$-154.52M
1 W Prestazione:
+4.71%
1M Prestazione:
+8.41%
6M Prestazione:
+51.23%
1 anno Prestazione:
+399.90%
Intervallo 1D:
$13.92
$15.25
Intervallo di 1 settimana:
$13.75
$15.70
Portata 52W:
$3.00
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Telefono
617-682-0917
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
15.04 | 1.55B | -665.00K | -149.28M | -154.52M | -1.7997 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Guggenheim | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-05-30 | Iniziato | TD Cowen | Buy |
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $34.00 - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2025 Earnings Call Transcript - Insider Monkey
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following Narrower Losses And New Shelf Filings - simplywall.st
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Reduced Losses And Late Stage Pipeline Progress - Yahoo Finance
Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About Amylyx Pharmac - GuruFocus
Amylyx Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Amylyx Pharmaceuticals at TD Cowen: Strategic Insights on Avexitide and More - Investing.com Canada
Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Amylyx Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Amylyx Pharmaceuticals Q4 2025 shows EPS beat By Investing.com - Investing.com India
Amylyx (AMLX) Q4 2025 Earnings Call Transcript - AOL.com
Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Amylyx Pharmaceuticals (NASDAQ:AMLX) Posts Earnings Results, Hits Expectations - MarketBeat
Stifel Nicolaus Initiates Coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals Q4 operating income USD -36.605 million versus. Ibes estimate USD -40.4 million - marketscreener.com
Amylyx Pharmaceuticals (AMLX) files S-3ASR shelf to sell stock, debt, warrants - Stock Titan
Amylyx Pharmaceuticals announced that its current cash reserves are expected to be sufficient to support the company's operations, not only covering the potential commercialization process of the new drug Avexitide, but also sustaining operations through 20 - Bitget
Stifel Initiates Amylyx Pharmaceuticals at Buy With $21 Price Target - marketscreener.com
Amylyx Pharmaceuticals Q4 Net Loss Narrows - marketscreener.com
AMYLYX PHARMACEUTICALS ($AMLX) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q4 Net Loss $0.30 a Share, vs. FactSet Est of $0.29 Loss - marketscreener.com
Amylyx shares fall over 3% on trial uncertainty despite earnings beat By Investing.com - Investing.com Australia
Amylyx Pharmaceuticals 10-K: $0M Revenue, $(0.29)–$(0.31) EPS range not stated - TradingView
Amylyx (Nasdaq: AMLX) advances PBH, ALS and Wolfram drugs - Stock Titan
Amylyx shares fall over 3% on trial uncertainty despite earnings beat - Investing.com UK
AMLX: Pivotal trial recruitment completed for avexitide in PBH; net loss narrowed and cash runway extends into 2028 - TradingView
Amylyx Pharmaceuticals (NASDAQ: AMLX) halves 2025 loss as PBH Phase 3 nears - Stock Titan
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Stifel initiates Amylyx stock with buy rating on drug potential By Investing.com - Investing.com Canada
AMLX (NASDAQ: AMLX) files Form 144 showing 17,105 RSU shares vesting - Stock Titan
AMLX (NASDAQ: AMLX) reports 20,545 RSUs vesting and two insider sales in Feb–Mar 2026 - Stock Titan
Retail Surge: Can Amylyx Pharmaceuticals Inc outperform under higher oil pricesMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
A Look at Amylyx Pharma's Upcoming Earnings Report - Benzinga
Amylyx set to report earnings as avexitide trial nears finish - Investing.com
AMLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amylyx Pharmaceuticals: 2026 Could Be Transformative Ahead of Avexitide Phase 3 Readout - Intellectia AI
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: A 41.98% Potential Upside Beckons Investors - DirectorsTalk Interviews
Amylyx Pharmaceuticals to Participate in Upcoming March 2026 Investor Conferences - BioSpace
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - The Joplin Globe
Amylyx Pharmaceuticals, Inc.Common Stock (NQ: AMLX - FinancialContent
Amylyx Pharmaceuticals (AMLX) CLO auto-sells 3,419 shares for taxes - Stock Titan
Amyotrophic Lateral Sclerosis Market: Expanding Revenue Landscape to 2034DelveInsight - openPR.com
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 - BioSpace
Top Amylyx Pharma Insider Makes Notable Move With Fresh Stock Sale - TipRanks
Issuer AMLX (NASDAQ: AMLX) proposes sale of 10,250 RSU shares on 02/23/2026 - Stock Titan
Patient Square Capital LP Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
GSA Capital Partners LLP Sells 118,426 Shares of Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Is Amylyx Pharmaceuticals Inc. a turnaround storyMarket Movement Recap & Safe Capital Growth Plans - mfd.ru
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.18%
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):